666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

• Minal Barve,
• Ahmad A Tarhini,
• Deepak Kilari,
• Rana Mckay,
• Randy Sweis,
• Timothy Yap,
• Justin Gainor,
• Raghad Karim,
• Lu Gan,
• Lan Liu,
• David Park,
• Ulka N Vaishampayan,
• Amna Sher,
• Sunil Babu,
• Yawen Ju,
• Susan Henry

Affiliations

Minal Barve

3Mary Crowley Cancer Research Center, Dallas, TX, USA

Ahmad A Tarhini

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Deepak Kilari

3Medical College of Wisconsin, Milwaukee, WI, USA

Rana Mckay

12Moores Cancer Center, University of California San Diego, La Jolla, CA, USA

Randy Sweis

8University of Chicago, Chicago, IL, USA

Timothy Yap

7The University of Texas, Houston, TX, USA

Justin Gainor

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

Raghad Karim

3NEXT Oncology, San Antonio, TX, USA

Lu Gan

1Scholar Rock, Cambridge, MA, USA

Lan Liu

Department of Radiology, Jiangxi Cancer Hospital, Nanchang, People`s Republic of China

David Park

2St Jude Crosson Cancer Institute, Fullerton, CA, USA

Ulka N Vaishampayan

8Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA

Amna Sher

9Stony Brook University, Stony Brook, NY, USA

Sunil Babu

11Fort Wayne Medical Oncology Hematology Inc, Fort Wayne, IN, USA

Yawen Ju

13Scholar Rock, Inc., Cambridge, MA, USA

Susan Henry

13Scholar Rock, Inc., Cambridge, MA, USA